PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarechale Cap. Regulatory News (MAC)

Share Price Information for Marechale Cap. (MAC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.35
Bid: 1.30
Ask: 1.40
Change: 0.00 (0.00%)
Spread: 0.10 (7.692%)
Open: 1.35
High: 1.35
Low: 1.35
Prev. Close: 1.35
MAC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Interim Results

17 Dec 2013 07:00

RNS Number : 6792V
Marechale Capital PLC
17 December 2013
 



17 December 2013

 

 

Marechale Capital plc

("Marechale Capital" or the "Company")

 

Interim Results

Marechale Capital plc today announces its unaudited interim results for the six months ended 30 September 2013.

Chairman's Statement

I am pleased to report that Marechale has made a very good start to the current year. On the back of improving economic sentiment, and more confidence in the equity markets, the Company's revenues are significantly ahead of where they were this time last year at £433,924 (2012 £140,682), an increase of 208%, and we are able to report that we have made a small profit of £18,915 (2012 loss £156,044) for the half year.

Marechale is acting for an increasing number of growth companies, and has successfully completed a series of transactions, which are all detailed on the Company's website at: www.marechalecapital.com. During the last six months a number of transactions that were started, in some cases, many months ago, have been completed, as well as more recently mandated business.

Marechale operates as a corporate finance advisory and capital fund raising business focusing on fundraising for growth companies in two primary sectors in which the team have a long term track record; Leisure and Retail, and Renewable Energy.

Marechale helps management teams to finance or refinance in two key areas of activity; Growth Capital private equity transactions for more established businesses, and Development Capital, fundraising for smaller growth companies, the latter typically being Enterprise Investment Scheme (EIS) qualifying. As part of Marechale's success fee, the Company secures warrants or equity on most of its projects, so shareholders have the opportunity to share in the potential significant upside of the equity value in these businesses. These investments are valued at cost or at a price that reflects their last funding round. The Board expects these to grow in value over the next few years.

One of the Company's initiatives in the renewables sector which we are pleased to provide an update on is the development of ultra large scale solar energy sites in the UK, through Marechale's joint venture company, Northfield UK Solar Limited (Northfield). Established in July this year, and first referred to in our last annual report and accounts, Northfield is developing a portfolio of solar sites; currently, it has signed exclusivity on approximately 350MW of large scale solar sites in the UK, on which it is aiming to secure grid connection offers and planning permission over the next few years. This is one of the larger solar energy initiatives in the UK, and, whilst it is difficult to attribute values until planning permissions and grid connections for the various sites have been secured, there is significant potential uplift value for Marechale's shareholders. The current fund raising round is in its final stages and is close to completing and, assuming that it achieves the maximum funding, Marechale's stake in Northfield will be around 28% of the enlarged equity, and would be Marechale's largest investment to date. This would be a post balance sheet item that is not reflected in these interim accounts.

In addition, Marechale completed the first stage funding of its anaerobic digestion EIS fund, which has been deployed to develop a 2MW AD plant in Norfolk. This is the fifth plant that Marechale's client, Future Biogas, has now built.

In other areas, the Company successfully completed a number of leisure deals, including the £10m equity and debt funding for Inn Collection, further endorsing Marechale's leading position in funding businesses in the leisure sector.

Whilst market conditions are still challenging, we are now more optimistic about the immediate outlook; there is also a healthy pipeline of new business that is being generated. Deal flow is picking up and, at our current level of 10, we have our largest number of engaged corporate finance projects to date. The year end results to March 2014 will be dependent on their outcome and whether the projects are completed before the year end.

There is an appetite amongst our investor relationships to invest in high quality investment opportunities. The Directors believe that backing the right growth companies, whilst not without its risks, represents an interesting private equity investment class for investors looking to diversify their portfolios. Over the last three and half years, if an investor had invested in each one of the 14 transactions Marechale has funded and completed, based on the last round of funding or exit value of these transactions, we calculate that they would have achieved an IRR of over 38% to date.

We will announce our full year's results in the summer of 2014.

 

Mark Warde-Norbury

Chairman

17 December 2013

 

For further information please contact:

 

Marechale Capital

Mark Warde-Norbury / Patrick Booth-Clibborn

 

Tel: +44 (0)20 7628 5582

Smith & Williamson Corporate Finance

Azhic Basirov / David Jones

 

Tel: +44 (0)20 7131 4000

 

 

Marechale Capital plc

Income Statement (unaudited)

Six months ended 30 September 2013

30 Sept

30 Sept

2013

2012

£

£

Revenue

433,924

140,682

Cost of sales

(167,741)

(32,211)

Gross profit

266,183

108,471

Administrative expenses

(260,711)

(278,015)

Operating profit/(loss)

5,472

(169,544)

Investment revenues

1,735

0

Other gains and losses

11,708

13,500

Profit/(loss) before tax

18,915

(156,044)

Corporation tax charge

0

0

Profit/(loss) for the period

18,915

(156,044)

 

Earnings per share (Basic and diluted)

57,681,151 shares (2012: 52,437,410)

0.04p

(0.30p)

 

 

Balance Sheet (unaudited)

As at 30 September 2013

30 Sept

30 Sept

2013

2012

£

£

Current assets

Available for sale investments

124,384

101,238

Trading investments

67,555

1,600

Trade and other receivables

214,306

129,176

Cash and cash equivalents

238,784

147,715

Total current assets

645,029

379,729

Current liabilities

Trade and other payables

(65,435)

(53,721)

Corporation tax

0

0

Total current liabilities

(65,435)

(53,721)

Net assets

579,594

326,007

Equity

Share capital

2,474,308

2,421,871

Share premium account

1,247,379

1,227,452

Revaluation reserves

39,635

16,989

Other reserves

(50,254)

(50,254)

Retained earnings

(3,131,474)

(3,290,051)

Total equity

579,594

326,007

 

Cash Flow Statement (unaudited)

Six months ended 30 September 2013

30 Sept

30 Sept

2013

2011

£

£

Net cash from operating activities

Operating profit /(loss)

5,473

(169,544)

Operating cash flows before movements in working capital

5,473

(169,544)

Movement in working capital

(Increase)/decrease in receivables

(21,742)

22,918

(Decrease)in payables

(20,607)

(908)

(42,349)

22,010

Operating cash flow

(36,876)

(147,534)

Investment activities

Interest receivable

1,734

0

Proceeds on disposal of trading investments

0

20,000

Proceeds on disposal of available for sale investments

11,708

(500)

Expenditure on tangible fixed assets

0

0

Expenditure on trading investments

0

(35,000)

Cash flow from investing activities

13,442

(15,500)

Financing

Issue of share capital

0

0

Interest payable

0

0

Cash flow from financing activities

0

0

Net increase/(decrease) in cash and cash equivalents

(23,434)

(163,034)

Cash and cash equivalents at start of period

262,218

310,749

Cash and cash equivalents at end of period

238,784

147,715

(Decrease)/ increase in cash and cash equivalents

(23,434)

(163,034)

 

 

This financial information has been prepared in accordance with IFRS and International Financial Reporting Interpretations Committee ('IFRIC') interpretations adopted by the European Union, and with those parts of the Companies Act 2006 applicable to companies reporting under IFRS, with the prior periods being reported on the same basis.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IR NKADPABDDCBD
Date   Source Headline
5th Dec 20237:00 amPRNHalf-year Report
22nd Nov 20231:00 pmPRNDirectorate Change
13th Oct 20233:51 pmPRNResult of AGM
19th Sep 20233:40 pmPRNNotice of AGM and Posting of Accounts
22nd Aug 20237:00 amPRNFinancial Statements for the Year Ended 30 April 2023
3rd Aug 202312:00 pmPRNHolding(s) in Company
28th Jun 20237:00 amPRNSubscription and Issue of Equity
2nd Mar 20227:00 amPRNPlacing, Subscription and Issue of Equity
1st Dec 20217:00 amPRNHalf-year Report
14th Oct 20213:28 pmRNSResult of AGM
11th Oct 20213:08 pmPRNHolding(s) in Company
8th Oct 20213:29 pmPRNHolding(s) in Company
5th Oct 20217:00 amPRNSubscription and Issue of Equity
22nd Sep 20212:57 pmPRNNotice of AGM
8th Sep 202111:54 amPRNHolding(s) in Company
7th Sep 20212:11 pmPRNDirector/PDMR Shareholding
23rd Aug 20217:00 amRNSFinal Results
12th Mar 20219:32 amPRNHolding(s) in Company
5th Mar 20211:29 pmPRNHolding(s) in Company
5th Mar 20218:50 amPRNHolding(s) in Company
4th Mar 20213:24 pmPRNTrading Update
4th Mar 20219:19 amPRNHolding(s) in Company
23rd Feb 20215:00 pmPRNHolding(s) in Company
23rd Feb 20217:00 amPRNDirector/PDMR Shareholding
10th Feb 20212:27 pmPRNHolding(s) in Company
10th Feb 20217:00 amPRNHolding(s) in Company
4th Feb 20219:15 amPRNExercise of Options and Issue of Equity
3rd Feb 20217:00 amPRNStatement re Share Price Movement
2nd Feb 20216:20 pmPRNHolding(s) in Company
26th Jan 202111:47 amPRNPlacing, Subscription and Issue of Equity
11th Dec 202012:47 pmPRNGrant of Options to Directors
24th Nov 20207:00 amPRNHalf-year Report
26th Oct 20201:16 pmPRNResult of AGM
2nd Oct 20207:00 amRNSChange of Adviser
28th Sep 20201:20 pmRNSPosting of Annual Report and Notice of AGM
25th Aug 202010:39 amRNSHolding(s) in Company
24th Aug 20207:00 amRNSFinal Results
10th Aug 202010:03 amRNSHolding(s) in Company
7th Aug 20201:05 pmRNSHolding(s) in Company
6th Aug 202010:09 amRNSHolding(s) in Company
5th Aug 202011:35 amRNSHolding(s) in Company
4th Aug 20201:03 pmRNSHolding(s) in Company
30th Jul 20204:40 pmRNSSecond Price Monitoring Extn
30th Jul 20204:35 pmRNSPrice Monitoring Extension
17th Jan 20203:31 pmRNSHolding(s) in Company
12th Dec 20193:08 pmRNSHalf-year Report
24th Sep 201912:16 pmRNSHolding(s) in Company
23rd Sep 20193:38 pmRNSResult of AGM
2nd Sep 20192:46 pmRNSPosting of Annual Report and Notice of AGM
29th Aug 20193:48 pmRNSFinal Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.